Table 1.
Baseline demographic and clinical characteristics of patients (N = 45)
| n | % | |
|---|---|---|
| Age, years | ||
| Median | 56 | |
| Range | 27–74 | |
| Receptor status | ||
| ER+/HER2− | 35 | 78 |
| ER+/HER2+ | 7 | 16 |
| ER+/HER2 unknown | 1 | 2 |
| Triple-negative | 2 | 4 |
| Histologic subtype | ||
| Invasive ductal | 37 | 82 |
| Invasive lobular | 3 | 7 |
| Other | 5 | 11 |
| Visceral metastases | ||
| Lung metastases | 18 | 40 |
| Liver metastases | 28 | 62 |
| Bone metastases | 33 | 73 |
| Prior hormonal therapy | 42 | 93 |
| Prior lines of chemotherapy | ||
| 0 | 1 | 2 |
| 1 | 4 | 9 |
| 2 | 16 | 36 |
| ≥3 | 24 | 53 |
| Prior taxane therapy | 36 | 80 |
| Prior anthracycline therapy | 32 | 71 |
| Prior bevacizumab | 19 | 42 |
ER estrogen receptor, HER2 human epidermal growth factor receptor-2, VEGF vascular endothelial growth factor